|Mr. Christopher A. Bunka||Chairman & CEO||144k||N/A||1962|
|Mr. John M. Docherty||Pres & Director||140.47k||N/A||1969|
|Mr. Allan Spissinger C.A., CPA||CFO, Corp. Sec. & Treasurer||85.66k||N/A||1969|
|Mr. Alex Blanchard||Mang. Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Dr. Edward Ergenzinger||Chief Legal Advisor and Sr. Advisor of Innovation||N/A||N/A||N/A|
Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods. It operates in two segments, Intellectual Property Licensing and Consumer Products. The company develops and licenses DehydraTECH, a patented lipid nutrient infusion technology that improves taste, rapidity, and delivery of bioactive compounds that include cannabinoids, vitamins, NSAIDs, nicotine, and other molecules. It is also involved in the development, production, and distribution of enhanced functional food and supplement products under the ViPova and Lexaria Energy brands. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.
Lexaria Bioscience Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.